Work

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma

Year: 2025

Type: article

Abstract: Standard pomalidomide dosing (4 mg/day for 21 of 28 days) achieved the most robust pharmacokinetic (PK) and pharmacodynamic (PD) effects. Daily dosing with pomalidomide 2 mg is a safe alternative for patients at risk of toxicity; alternate-day dosing was less effective.

Source: British Journal of Haematology

DOI: 10.1111/bjh.70239

Authors: M. R. Seefat, D. G. J. Cucchi, L. van Boven, N. Durdu‐Rayman, K. Groen, M.‐D. Levin, K. de Heer, B. de Valk, R. Wester, E. van der Spek, R. Rentenaar, C. L. B. M. Korst, M. Quik, C. A. O'Neill, P. Tzortzi, F. Smits, R. Mathot, M. R. Heerma van Voss, N. W. C. J. van de Donk, T. Mutis, I. H. Bartelink, S. Zweegman

Institutions: Amsterdam University Medical Centers, Cancer Center Amsterdam, Sint Franciscus Gasthuis, Franciscus Vlietland, Albert Schweitzer Ziekenhuis, Flevoziekenhuis, Spaarne Ziekenhuis, Spaarne Gasthuis, Erasmus MC, Erasmus MC Cancer Institute, Rijnstate Hospital, Haga Hospital

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,190

OpenAlex ID: W4415788346

FWCI: 1.277

Cites: 14

Cited by: 2

Related to: